Investigation of the bcl-2 and c-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia

International Journal of Gynecological Pathology

Volumn 16, Issue 3, 1997, Pages 212-218

  Dellas, Athanassios ^a   Schultheiss, Elisabeth ^a   Holzgreve, Wolfgang ^a   Oberholzer, Martin ^a   Torhorst, Joachim ^a   Gudat, Fred ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bcl 2; C myc; CIN; Immunohistochemistry; Ki 67 labelling index

Indexed keywords

KI 67 ANTIGEN; MYC PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS EPITHELIUM; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 0031002443     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199707000-00004     Document Type: Article

References (29)

1. McDonnell TJ, Marin MC, Hsu B, et al. The bcl-2 oncogene: apoptosis and neoplasia. Radiat Res 1993;136:307-12.
2. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
3. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-43.
4. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986;47:19-28.
5. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.) 1990;348:334-6.
6. Nunez G, London L, Hockenbery DM, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth-factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-10.
7. Liang XH, Mungal S, Ayscue A, et al. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995;57:509-21.
8. Hockenbery DM. bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl 1994;18:51-5.
9. Bissonnette RP, Echeveri F, Mahboubi A, Green D. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992;359: 552-4.
10. Fanidi A, Harrington EA, Evan G. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554-6.
11. Godwin AK, Hamilton TC, Knudson AG, Jr. Oncogenes and antioncogenes. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: J. B. Lippincott Company, 1992:87-116.
12. Bai MK, Costopoulos JS, Christoforidou BP, Papadimitriou CS. Immunohistochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology 1994;51:314-19.
13. Kelly K, Sibenlist U. The regulation and expression of c-myc in normal and malignant cells. Ann Rev Immunol 1986;4:317-38.
14. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
15. Lee JT, Innes DJ, Williams ME. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 1989;84:1454-9.
16. Riou G, Barrois M, Le MG, George M, Le Doussal V, Haie C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 1987;1(8536):761-3.
17. Riou GF, Bourhis J, Le MG. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Res 1990;10: 1225-31.
18. Sowani A, Ong G, Dische S, et al. c-myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes 1989;3:117-23.
19. Bourhis J, Le MG, Barrois M, et al. Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990;8:1789-96.
20. Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 1987;84:1070-74.
21. Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995;76:2297-2303.
22. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993;53:4701-14.
23. Vaux D, Cory S, Adams J. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.) 1988;335:440-2.
24. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
25. Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surv 1992;15:105-18.
26. Dellas A, Schultheiss E, Almendral AC, Torhorst J, Gudat F. Assessment of EGFR and TGF-alpha expression in relationship to the HPV status and the Ki-67 distribution in cervical intraepithelial neoplasm. Int J Cancer 1996;69:165-9.
27. Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, Hardwick JM. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (Lond.) 1993;361:739-42.
28. Devictor B, Bonnier P, Piana L, Andrac L, Lavaut MN, Allasia C, Charpin C. c-myc Protein and Ki-67 antigen immunodetection in patients with uterine cervix neoplasia: Correlation of microcytophotometric analysis and histological data. Gynecol Oncol 1993; 49:284-90.
29. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.